|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 365.83 USD | +0.32% |
|
-0.01% | +11.87% |
| 02-10 | Mizuho Raises Price Target on Amgen to $295 From $280, Keeps Outperform Rating | MT |
| 02-10 | Daiwa Securities Adjusts Price Target on Amgen to $410 From $370, Maintains Outperform Rating | MT |
Business description: Amgen Inc.
- drug sales (95.8%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other 4.2%): primarily royalties.
The United States account for 71.4% of net sales.
Number of employees: 28,000
Sales by Activity: Amgen Inc.
| Fiscal Period: December | 2020 (USD) | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) |
|---|---|---|---|---|---|
Human Therapeutics | 25.42B | 25.98B | 26.32B | 28.19B | 33.42B |
Geographical breakdown of sales: Amgen Inc.
| Fiscal Period: December | 2020 (USD) | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) |
|---|---|---|---|---|---|
United States (U.S.) | 18.5B | 18.19B | 18.6B | 19.81B | 23.86B |
Rest of The World (Row) | 6.93B | 7.78B | 7.73B | 8.38B | 9.56B |
Executive Committee: Amgen Inc.
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Bradway
CEO | Chief Executive Officer | 63 | 30/04/2012 |
Peter Griffith
DFI | Director of Finance/CFO | 67 | 31/12/2019 |
Esteban Santos
COO | Chief Operating Officer | 59 | 24/07/2016 |
Howard Y. Chang
CTO | Chief Tech/Sci/R&D Officer | - | 15/12/2024 |
Paul Burton
CTO | Chief Tech/Sci/R&D Officer | 57 | 31/05/2023 |
Composition of the Board of Directors: Amgen Inc.
| Director | Title | Age | Since |
|---|---|---|---|
Robert Bradway
CHM | Chairman | 63 | 31/12/2012 |
Tyler Jacks
BRD | Director/Board Member | 65 | 31/12/2011 |
Robert Eckert
BRD | Director/Board Member | 71 | 31/12/2011 |
Greg Garland
BRD | Director/Board Member | 68 | 15/10/2013 |
Ellen Kullman
BRD | Director/Board Member | 70 | 13/10/2016 |
Charles Holley
BRD | Director/Board Member | 69 | 02/02/2017 |
Wanda Austin
BRD | Director/Board Member | 71 | 23/10/2017 |
Brian Druker
BRD | Director/Board Member | 70 | 22/05/2018 |
Amy Miles
BRD | Director/Board Member | 59 | 22/07/2020 |
Omar Ishrak
BRD | Director/Board Member | 71 | 29/07/2021 |
Holdings: Amgen Inc.
| Name | Equities | % | Valuation |
|---|---|---|---|
NEUMORA THERAPEUTICS, INC. 21.17% | 35,368,653 | 21.17% | 70 M $ |
Company details: Amgen Inc.
Group companies: Amgen Inc.
| Name | Category and Sector |
|---|---|
Amgen NV
 Amgen NV Pharmaceuticals: MajorHealth Technology Develops and commercializes medicines for patients with serious illness |
Pharmaceuticals: Major
|
Amgen NV
Amgen NV Pharmaceuticals: MajorHealth Technology Develops and commercializes medicines for patients with serious illness |
Pharmaceuticals: Major
|
Amgen Global Finance BV
 Amgen Global Finance BV MiscellaneousMiscellaneous Functions as an investment holding company and provides financing services |
Miscellaneous
|
Other Pharmaceuticals
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.32% | -0.01% | +23.43% | +50.28% | 196B | |
| -0.29% | -7.53% | +18.35% | +192.17% | 918B | |
| +0.93% | +2.64% | +54.14% | +47.87% | 574B | |
| -0.62% | +1.80% | +15.22% | +43.77% | 393B | |
| +1.62% | -1.05% | +23.80% | +27.79% | 366B | |
| +1.74% | +3.71% | +25.56% | +53.07% | 301B | |
| +4.62% | +7.41% | +27.48% | +29.73% | 300B | |
| +1.22% | +0.04% | +36.79% | +8.06% | 291B | |
| -2.62% | +0.67% | -48.90% | -38.29% | 223B | |
| +5.60% | +6.33% | +61.72% | +77.71% | 183B | |
| Average | +1.17% | +0.97% | +23.76% | +49.22% | 374.54B | |
| Weighted average by Cap. | +0.84% | +1.32% | +25.17% | +73.17% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- AMGN Stock
- Company Amgen Inc.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition